Savara Inc Revenue from Contract with Customer, Excluding Assessed Tax
Savara Inc (SVRA) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-03-30
- Savara Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Savara Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $1.00K.
- Savara Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $256.00K.
- Savara Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $0.00.
- Savara Inc revenue from contract with customer, excluding assessed tax for fiscal 2020 was $257.00K.
- Savara Inc revenue from contract with customer, excluding assessed tax for fiscal 2019 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $257.00K derived: sum of 2 quarters · filed 2022-03-30 | $257.00K derived: sum of 3 quarters · filed 2022-03-30 | $257.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $256.00K 10-Q · filed 2021-11-12 | $256.00K derived: sum of 2 quarters · filed 2021-11-12 | $256.00K 10-Q · filed 2021-11-12 | $256.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-08-06 | $0.00 derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-05-07 | $0.00 derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $0.00 10-K · filed 2020-03-12 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |